APM
ANIK icon

Avidity Partners Management’s Anika Therapeutics ANIK Stock Holding History

Avidity Partners Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-731,000
Closed -$33.1M – 96
2020
Q4 		$33.1M Buy
731,000
+129,300
+21% +$4.91M 1.07% 34
2020
Q3 		$21.3M Buy
601,700
+239,210
+66% +$8.64M 0.99% 31
2020
Q2 		$13.7M Buy
362,490
+194,490
+116% +$6.41M 0.88% 43
2020
Q1 		$4.86M Buy
+168,000
New +$6.8M 0.67% 47

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

Avidity Partners Management's ANIK Position: Q1 2021 in Review

Avidity Partners Management sold out of Anika Therapeutics (ANIK) in Q1 2021, closing a stake of 731,000 shares — an estimated $33.1M sold.

Avidity Partners Management first reported a position in ANIK in Q1 2020 and held it in 4 quarters. The position peaked at $33.1M in Q4 2020. 145 funds tracked by Wall St. Rank hold ANIK as of Q1 2021.

  • Avidity Partners Management reported no remaining Anika Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Avidity Partners Management sold 731,000 Anika Therapeutics shares in Q1 2021, an estimated $33.1M.
  • Avidity Partners Management first reported a position in Anika Therapeutics in Q1 2020 and held it in 4 quarters.
  • Avidity Partners Management's Anika Therapeutics position peaked at $33.1M in Q4 2020.
  • 145 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2021.

Based on Avidity Partners Management's 13F filing for Q1 2021, filed 17 May 2021.